Joint Formulary & PAD

Glycopyrronium with indacaterol (Ultibro Breezhaler) - Chronic Obstructive Pulmonary Disease (COPD)

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

PAD Profile

ChemicalSubstance :
Glycopyrronium with indacaterol (Ultibro Breezhaler)
Indication :
Chronic Obstructive Pulmonary Disease (COPD)
Group Name :
LAMA LABA
Keywords :
LAMA LABA, LAMA/LABAs, LABA/LAMAs, antimuscarinic bronchodilators, respiratory
Brand Names Include :
Ultibro Breezhaler
Important Information :

Second line - low-resistance device so patients must inhale faster to generate the power to separate the drug molecules, which may be difficult in patients with poor lung function.

Prescribe by BRAND

Latest Additions Date From :
Latest Additions Date To :
Supporting Documents :
5

Other Indications

Below are listed other indications that Glycopyrronium with indacaterol (Ultibro Breezhaler) is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Chronic Obstructive Pulmonary Disease (COPD).

Committee Recommendations (1)

The locally preferred LAMA/LABA devices are as follows:

  • Spiolto Respimat (tiotropium / olodaterol soft mist inhaler). Re-usable device.
  • Anoro Ellipta (Umeclidinium / vilanterol DPI)
  • Ultibro Breezhaler (Glycopyrronium / indacaterol DPI)
  • Duaklir Genuair (Aclidinium / formoterol DPI)

Devices should be prescribed by BRAND

See full COPD guidelines for more information